Market Capitalization (Millions $) |
0 |
Shares
Outstanding (Millions) |
3 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-32 |
Cash Flow (TTM) (Millions $) |
-20 |
Capital Exp. (TTM) (Millions $) |
0 |
Eloxx Pharmaceuticals Inc
Eloxx Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics for genetic diseases. The company focuses on genetic diseases caused by nonsense mutations, which are mutations that prematurely stop the production of functional proteins. Eloxx develops small molecule drugs called ribosomal selective glycosides (RSGs) that can enable the ribosome to bypass the mutated part of the gene and continue protein synthesis, leading to the production of functional proteins. The company's lead product candidate, ELX-02, is being developed to treat cystic fibrosis and other diseases caused by nonsense mutations. Eloxx Pharmaceuticals aims to provide innovative treatment options for patients with genetic diseases where limited therapeutic options currently exist.
Company Address: 480 Arsenal Way Watertown 2472 MA
Company Phone Number: 577-5300 Stock Exchange / Ticker: NASDAQ ELOX
|